The PKD Research Consortium: Advancing the Fight Against Polycystic Kidney Disease
Polycystic kidney disease (PKD) is the world’s most common inherited kidney disease, with substantial unmet needs and limited treatment options. In collaboration with Kidney Research UK, we've embarked on a transformative mission, dedicated to advancing PKD research and development.
We’re forming a groundbreaking PKD Research Consortium, which will bring together scientific and clinical experts to accelerate treatment development and transform the lives of people living with PKD.
Our vision for the PKD Research Consortium
Our aim for the consortium is to combine experimental modelling, genetic and clinical data to generate insights and identify ways to treat PKD. The consortium will drive collaboration in this area and find new targets for drug development, or repurposing, to improve outcomes for patients.
Consultancy support needed
We’re looking for a consultancy who can undertake a scoping study to help us establish the PKD Research Consortium.
The proposed scoping study will be required to include:
- governance guidance and support
- information collection from stakeholders and intended academic centres
- identifying the barriers and opportunities for clinical trials.
Find out more
For more information about the PKD Research Consortium, and the scoping study requirements, download our PKD Consortium Consultancy Briefing document. Alternatively, if you have any questions or would like to discuss it further, contact Alan Greenberg, PKD Charity chair of trustees.
If your organisation can help support us, please send an expressions of interest to by 21 July 2023.
- Hits: 1881